Antonio Calles

3.9k total citations
88 papers, 1.9k citations indexed

About

Antonio Calles is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Antonio Calles has authored 88 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Antonio Calles's work include Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (19 papers) and Cancer Genomics and Diagnostics (15 papers). Antonio Calles is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Lung Cancer Research Studies (19 papers) and Cancer Genomics and Diagnostics (15 papers). Antonio Calles collaborates with scholars based in Spain, United States and France. Antonio Calles's co-authors include Pasi A. Jänne, Geoffrey R. Oxnard, Mohit Butaney, Emiliano Calvo, Christine Lydon, Lynette M. Sholl, Rosa Álvarez, Jonathan W. Riess, Scott J. Rodig and Julie R. Brahmer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Antonio Calles

83 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Calles Spain	22	1.3k	752	643	362	277	88	1.9k
Giuseppe Lo Russo Italy	24	1.3k 1.0×	731 1.0×	567 0.9×	371 1.0×	203 0.7×	145	2.0k
Karijn P.M. Suijkerbuijk Netherlands	24	1.3k 1.1×	432 0.6×	675 1.0×	321 0.9×	305 1.1×	119	2.0k
Alex Friedlaender Switzerland	28	1.5k 1.2×	1.1k 1.5×	711 1.1×	437 1.2×	263 0.9×	86	2.3k
Harpreet Singh United States	24	1.0k 0.8×	647 0.9×	495 0.8×	427 1.2×	178 0.6×	101	1.8k
Ben Creelan United States	26	1.4k 1.2×	937 1.2×	598 0.9×	361 1.0×	518 1.9×	94	2.2k
Adam J. Schoenfeld United States	23	1.5k 1.2×	1.0k 1.3×	576 0.9×	330 0.9×	477 1.7×	77	2.3k
Penelope A. Bradbury Canada	29	1.1k 0.9×	1.1k 1.5×	604 0.9×	419 1.2×	150 0.5×	112	2.0k
Kristen A. Marrone United States	16	1.5k 1.2×	761 1.0×	458 0.7×	190 0.5×	418 1.5×	74	2.0k
Wade T. Iams United States	21	1.4k 1.1×	718 1.0×	806 1.3×	514 1.4×	459 1.7×	95	2.2k
Giulia Pasello Italy	23	1.1k 0.9×	1.1k 1.5×	510 0.8×	349 1.0×	155 0.6×	165	2.0k

Countries citing papers authored by Antonio Calles

Since Specialization

Citations

This map shows the geographic impact of Antonio Calles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Calles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Calles more than expected).

Fields of papers citing papers by Antonio Calles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Calles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Calles. The network helps show where Antonio Calles may publish in the future.

Co-authorship network of co-authors of Antonio Calles

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Calles. A scholar is included among the top collaborators of Antonio Calles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Calles. Antonio Calles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Casarini, Ignacio, Tibor Csőszi, Mehmet Alı Nahıt Şendur, et al.. (2025). Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Annals of Oncology. 36(7). 775–785. 4 indexed citations

Italiano, Antoine, Hossein Borghaei, Sanjay Popat, et al.. (2024). 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study. Immuno-Oncology Technology. 24. 100747–100747. 3 indexed citations

Calles, Antonio, Emiliano Calvo, Gema Santamaría Núñez, et al.. (2024). Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer. Molecular Cancer Therapeutics. 24(6). 828–839. 4 indexed citations

Calles, Antonio, et al.. (2023). Unleashing a Lazarus Effect With Selpercatinib in a Never-Smoker Patient With Stage IV, Chemo-Immunotherapy Refractory, RET C630Y-Mutant, Small-Cell Lung Cancer: A First Case Report. JCO Precision Oncology. 7(7). e2300321–e2300321. 1 indexed citations

Besse, Benjamin, Melissa L. Johnson, S-H.I. Ou, et al.. (2022). 78TiP Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase I/II ARROS-1 study. Annals of Oncology. 33. S68–S69. 1 indexed citations

Russo, Alessandro, et al.. (2022). 1007P Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC. Annals of Oncology. 33. S1013–S1014. 2 indexed citations

Morgan, Gilberto, Marco Tagliamento, Matteo Lambertini, et al.. (2021). Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open. 6(2). 100104–100104. 17 indexed citations

Calles, Antonio, et al.. (2020). Impact of COVID-19 in continuity ofcancer treatment for lung cancer patients. Clinical Cancer Research. 26(18). 1 indexed citations

Álvarez, Rosa, Antonio Calles, Carlos López, et al.. (2019). Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. Clinical & Translational Oncology. 22(4). 555–562. 14 indexed citations

10.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations

11.

Márquez‐Rodas, Iván, Federico Longo, María E. Rodríguez-Ruiz, et al.. (2018). Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. Annals of Oncology. 29. viii732–viii732. 7 indexed citations

12.

Kosaka, Takayuki, Junko Tanizaki, Raymond M. Paranal, et al.. (2017). Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Research. 77(10). 2712–2721. 100 indexed citations

13.

Calvo, Aitana, Sara López‐Tarruella, Rosa Álvarez, et al.. (2017). Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. Annals of Oncology. 28. v135–v135.

14.

Rodríguez‐Vicente, Ana E., Eva Lumbreras, Jesús María Hernández-Sánchez, et al.. (2016). Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metabolism and Personalized Therapy. 31(1). 25–34. 20 indexed citations

15.

Calles, Antonio, Lynette M. Sholl, Scott J. Rodig, et al.. (2015). Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma. Clinical Cancer Research. 21(12). 2851–2860. 86 indexed citations

16.

Tanizaki, Junko, Dalia Ercan, Marzia Capelletti, et al.. (2015). Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. Cancer Research. 75(15). 3139–3146. 30 indexed citations

17.

Wilson, Frederick H., Cory M. Johannessen, Federica Piccioni, et al.. (2015). A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. Cancer Cell. 27(3). 397–408. 130 indexed citations

18.

Azaro, Analía, Jordi Rodón, Antonio Calles, et al.. (2015). A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Investigational New Drugs. 33(3). 710–719. 25 indexed citations

19.

Garralda, Elena, Keren Paz, Pedro P. López‐Casas, et al.. (2014). Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research. 20(9). 2476–2484. 107 indexed citations

20.

García-Sáenz, José Á., Miguel Martín, Antonio Calles, et al.. (2008). Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer. Journal of Chemotherapy. 20(5). 632–639. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact